Sentinel Node Biopsy in Melanoma: What Trials Show

A sentinel lymph node biopsy asks whether a cutaneous melanoma has reached the first regional node or nodes in its lymphatic drainage pathway. Its central value is staging and prognosis: a positive result can move a clinically node-negative melanoma into pathologic stage III, refine recurrence estimates, affect surveillance, and influence eligibility for adjuvant treatment discussions or trials.

The procedure is not the same as completion lymph node dissection. Sentinel biopsy removes a small number of mapped nodes. Completion dissection removes the remaining nodes in that basin after a positive sentinel result. MSLT-II tested the second procedure and found better regional control but no improvement in melanoma-specific survival from routine immediate dissection compared with structured ultrasound observation.

What the sentinel procedure measures#

Lymph from a patch of skin usually drains first to one or a few nodes. Before surgery, a tracer is placed near the melanoma site and lymphatic mapping identifies the initial basin and node, and the surgeon removes the mapped sentinel nodes, and pathology examines them for melanoma deposits.

A negative sentinel node lowers the probability that regional nodes contain melanoma, but no test is perfect. Drainage can be complex, a true sentinel node may not be identified, and small deposits can be missed, so the result must be interpreted with the primary tumor and the technical quality of mapping and pathology.

A positive result provides more than a yes-or-no label; the size and location of the deposit, number of involved sentinel nodes, extranodal extension, primary thickness, ulceration, and in-transit or satellite disease affect prognosis. Staging systems combine these features rather than treating every positive node as equivalent.

AJCC eighth edition changed thin-melanoma categories. T1a is less than 0.8 mm without ulceration. T1b includes melanoma from 0.8 to 1.0 mm with or without ulceration, or below 0.8 mm with ulceration, and nodal information contributes to pathologic stage grouping and can separate clinically occult from clinically apparent node disease.

Who is usually offered discussion of biopsy#

The 2018 ASCO and Society of Surgical Oncology guideline update does not recommend routine sentinel biopsy for T1a melanoma; it says biopsy may be considered for T1b after a thorough discussion of potential benefit and harm. It recommends the procedure for intermediate-thickness melanoma and says it may be recommended for thick melanoma for staging and regional disease control.

Guidelines are not a substitute for a current specialty assessment. Pathology terminology, systemic therapy, staging, and local practice change over time, and the useful question is whether finding occult nodal disease would change your prognosis, additional testing, treatment options, surveillance, or trial access enough to justify the burdens of the procedure.

Potential harms include pain, infection, seroma, sensory change, anesthetic complications, and lymphedema. The risk is generally lower than with a full nodal dissection, but it is not zero. Mapping can also identify unexpected drainage basins that change the surgical plan.

MSLT-I tested a biopsy-based strategy#

MSLT-I randomly assigned people with clinically localized melanoma to wide excision plus sentinel node biopsy, with immediate completion dissection when the sentinel node was positive, or to wide excision plus nodal observation, with dissection if nodal disease later became clinically apparent.

The final report found no significant difference in 10-year melanoma-specific survival in the overall randomized comparison, but disease-free survival was higher in biopsy groups for intermediate-thickness and thick melanomas, partly because early nodal detection changed the timing and classification of recurrence.

The report also described favorable survival among the subgroup with nodal metastases detected through biopsy compared with people whose nodal disease appeared later, though that comparison is harder to interpret causally because membership in those subgroups is determined after randomization. People whose occult disease is found early are not necessarily exchangeable with people whose disease later becomes clinically apparent. What survives from the trial is that sentinel status is strongly prognostic and that the strategy improves pathologic staging and regional disease information, and a favorable post-randomization subgroup does not replace the overall randomized survival result.

A positive sentinel node created a second question#

For years, a positive sentinel result routinely led to completion dissection. The rationale was to remove additional occult disease, improve basin control, and learn whether nonsentinel nodes were involved. The costs included a larger operation and higher risk of chronic lymphedema.

Most completion specimens contain no additional positive nodes. The question therefore became whether operating on everyone with a positive sentinel node improved survival enough to justify morbidity, or whether close ultrasound surveillance could identify regional progression while avoiding many dissections.

MSLT-II randomly assigned participants with sentinel-node metastases to immediate completion dissection or observation with scheduled nodal ultrasonography and clinical follow-up. Delayed therapeutic dissection remained available if nodal recurrence developed. Observation was an active protocol, not absence of care.

What MSLT-II found#

At three years, melanoma-specific survival was approximately 86% in both groups, so immediate completion dissection did not improve the trial's primary survival endpoint. Disease-free survival was modestly higher with dissection, driven largely by better control of nodal recurrence. Control is not survival.

The dissection group had more information because pathology identified nonsentinel-node metastases in about 11.5% of participants. That finding was prognostic. The operation also increased the rate of regional nodal control. These are real benefits, but they are different from longer melanoma-specific survival.

Lymphedema occurred in 24.1% of participants in the dissection group and 6.3% in the observation group. That absolute difference makes the trade-off concrete. A procedure can improve local control and staging information while causing more chronic morbidity and leaving the primary survival outcome unchanged. The DeCOG-SLT randomized trial reached a compatible conclusion about routine completion dissection, although it was smaller and had its own limitations. Together, the trials changed guidelines away from automatic dissection for every positive sentinel node.

What the trial did not prove#

MSLT-II does not say completion dissection is never appropriate. Participants were selected for a trial, most had relatively low sentinel-node tumor burden, and high-quality repeated ultrasound was central to the observation strategy. People with clinically apparent nodal disease, bulky involvement, inability to receive surveillance, or other features may face a different decision.

The trial also predates parts of the current adjuvant-therapy landscape. Systemic treatment options can change the value of pathologic staging and the consequences of regional recurrence, and applying the result requires current melanoma expertise and access to the monitoring used in the observation arm.

Three-year equivalence does not mean every secondary outcome was identical. Regional control, additional nodal information, surgical morbidity, anxiety, follow-up burden, and later operations differ. A decision should name which outcome it is trying to improve.

Prognostic value is not therapeutic benefit#

A prognostic test separates people with different future risks. A therapeutic intervention changes that future. Sentinel-node status clearly carries prognostic information. Whether the act of finding and removing occult disease improves survival is a separate causal question.

This distinction appears throughout medicine. Imaging can stage a cancer accurately without improving survival unless a resulting treatment helps. A biomarker can identify high risk without being a useful treatment target. A trial should test the intervention pathway, not infer benefit from prognostic separation.

Sentinel biopsy also has procedural effects because it removes the mapped node, and the MSLT-I strategy bundled biopsy with completion dissection for positive results. That complexity is another reason to avoid one-line claims that the procedure either “saves lives” or “does nothing.” The randomized estimand and comparison must be named.

Reading absolute effects#

Relative measures are useful, but surgical choices become clearer with absolute outcomes. In MSLT-II, the primary survival proportions were essentially the same at three years, while lymphedema differed by about 18 percentage points. Regional recurrence favored dissection. Those outcomes should not be compressed into one verdict.

Absolute effects can differ when baseline risk differs. A person with a very small sentinel deposit and reliable ultrasound access may value avoiding lymphedema. Someone with higher nodal burden, difficult surveillance, or a strong priority for regional control may weigh the same evidence differently. The evidence frames the choice; it does not supply your values.

A practical evidence checklist#

If you are facing a sentinel biopsy decision, confirm the pathology review, Breslow thickness, ulceration, margins, and any features affecting nodal risk. Ask how the result would change your stage, the systemic treatment discussion, imaging, surveillance, or trial options. Ask as well about mapping success, operative risks, false-negative possibility, and local expertise.

After a positive result, separate three questions: whether more nodal information is needed, whether regional control would improve with surgery, and whether surgery changes survival. If observation is on the table, pin down the ultrasound frequency, the expertise behind it, the adherence it asks of you, and what happens when a node looks suspicious.

The guides to moles and melanoma warning patterns and skin checks cover earlier parts of the pathway. The site's clinical strengths overview connects careful risk communication to shared decisions.

References#

1. MSLT-I final randomized trial report
2. MSLT-II completion dissection versus observation
3. ASCO and SSO sentinel node guideline update
4. AJCC eighth edition melanoma staging evidence
5. Final analysis of DeCOG-SLT

For your own health, talk with your clinician.*